BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 18292936)

  • 1. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
    Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
    Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
    Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
    Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The growth hormone-releasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line.
    Annunziata M; Grande C; Scarlatti F; Deltetto F; Delpiano E; Camanni M; Ghigo E; Granata R
    Fertil Steril; 2010 Aug; 94(3):841-9. PubMed ID: 19524226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
    Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S
    Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition.
    Köster F; Engel JB; Schally AV; Hönig A; Schröer A; Seitz S; Hohla F; Ortmann O; Diedrich K; Buchholz S
    Breast Cancer Res Treat; 2009 Jul; 116(2):273-9. PubMed ID: 18629632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
    Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
    Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor.
    Barabutis N; Siejka A; Schally AV; Block NL; Cai R; Varga JL
    J Mol Endocrinol; 2010 Feb; 44(2):127-34. PubMed ID: 19897610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
    Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
    Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of growth hormone-releasing hormone receptor splice variant 1 in primary human melanomas.
    Chatzistamou I; Volakaki AA; Schally AV; Kiaris H; Kittas C
    Regul Pept; 2008 Apr; 147(1-3):33-6. PubMed ID: 18255167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
    Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G
    Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
    Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
    Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.
    Pozsgai E; Schally AV; Hocsak E; Zarandi M; Rick F; Bellyei S
    Int J Oncol; 2011 Oct; 39(4):1025-32. PubMed ID: 21701777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
    Engel JB; Keller G; Schally AV; Toller GL; Groot K; Havt A; Armatis P; Zarandi M; Varga JL; Halmos G
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3614-21. PubMed ID: 15784701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart.
    Granata R; Trovato L; Gallo MP; Destefanis S; Settanni F; Scarlatti F; Brero A; Ramella R; Volante M; Isgaard J; Levi R; Papotti M; Alloatti G; Ghigo E
    Cardiovasc Res; 2009 Jul; 83(2):303-12. PubMed ID: 19293247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone-releasing hormone antagonist induces apoptosis of human endometrial cancer cells through PKCδ-mediated activation of p53/p21.
    Wu HM; Schally AV; Cheng JC; Zarandi M; Varga J; Leung PC
    Cancer Lett; 2010 Dec; 298(1):16-25. PubMed ID: 20630651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
    Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S
    Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of growth hormone-releasing hormone (GHRH) and GHRH antagonist (MZ-4-71) on interferon-gamma secretion from human peripheral blood mononuclear cells in vitro.
    Siejka A; Ławnicka H; Komorowski J; Stepień T; Krupiński R; Stepień H
    Neuropeptides; 2004 Feb; 38(1):35-9. PubMed ID: 15003714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of growth hormone-releasing hormone (GHRH) and splice variant of GHRH receptors in normal mouse tissues.
    Christodoulou C; Schally AV; Chatzistamou I; Kondi-Pafiti A; Lamnissou K; Kouloheri S; Kalofoutis A; Kiaris H
    Regul Pept; 2006 Sep; 136(1-3):105-8. PubMed ID: 16781787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132.
    Volakaki AA; Lafkas D; Kassi E; Schally AV; Papavassiliou AG; Kiaris H
    J Mol Endocrinol; 2008 Nov; 41(5):389-92. PubMed ID: 18765563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues.
    Borri P; Coronnello M; Noci I; Pesciullesi A; Peri A; Caligiani R; Maggi M; Torricelli F; Scarselli G; Chieffi O; Mazzei T; Mini E
    Gynecol Oncol; 1998 Dec; 71(3):396-403. PubMed ID: 9887238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.